# Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.

> **NCT04795661** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Centre Leon Berard** · enrollment: 240 (estimated)

## Conditions studied

- Localized Resectable Tumor
- MSI/dMMR

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04795661
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-18
- **Primary completion:** 2023-10-05
- **Final completion:** 2029-10
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04795661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04795661, "Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04795661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*